Over-the-Counter Pain Reliever and Aspirin Use Within a Sample of Long-term Cyclooxygenase 2 Users
- 14 June 2004
- journal article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 164 (11) , 1243-1246
- https://doi.org/10.1001/archinte.164.11.1243
Abstract
The Celecoxib Long-term Arthritis Safety Study (CLASS) evaluated the adverse gastrointestinal (GI) effects caused by the use of the selective cyclooxygenase 2 (COX-2) drug celecoxib and nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with osteoarthritis and rheumatoid arthritis.1 The study found no significant difference in the GI ulcer complication rate (ie, bleeding, perforation, or obstruction in the GI tract) between celecoxib and nonselective NSAIDs. The authors attributed this finding to a higher-than-anticipated aspirin comedication rate of 21% among study participants, a rate almost double that of previous clinical trial experience. Since usage patterns in clinical trials and routine clinical practice often differ, the purpose of the present study was to estimate aspirin comedication rates among long-term COX-2 users. To provide a thorough description of over-the-counter (OTC) NSAID and pain reliever use, we also examine comedication with 2 other OTC NSAIDs (ie, ibuprofen and naproxen sodium) and another commonly used OTC pain reliever, acetaminophen.This publication has 17 references indexed in Scilit:
- Recent Patterns of Medication Use in the Ambulatory Adult Population of the United StatesJAMA, 2002
- Relative Risk of Upper Gastrointestinal Complications among Users of Acetaminophen and Nonsteroidal Anti-Inflammatory DrugsEpidemiology, 2001
- Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulationsBMC Clinical Pharmacology, 2001
- Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesionsAlimentary Pharmacology & Therapeutics, 1999
- Protection of human gastric mucosa against aspirin—enteric coating or dose reduction?Alimentary Pharmacology & Therapeutics, 1999
- Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered productThe Lancet, 1996
- A Chronic Disease Score with Empirically Derived WeightsMedical Care, 1995
- Risk of upper gastrointestinal bleeding and perforation associated with Individual non-steroidal anti-inflammatory drugsThe Lancet, 1994
- The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials.British Journal of Clinical Pharmacology, 1993
- Aspirin‐induced gastric mucosal damage: prevention by enteric‐coating and relation to prostaglandin synthesis.British Journal of Clinical Pharmacology, 1991